Manufacturers performing service activities must document procedures, maintain records, and treat reports of events meeting MDR criteria as complaints. FDA has historically scrutinized 'right to service' between OEMs and third-party servicers. Under the QMSR, servicing requirements now follow ISO 13485 clause 7.5.4, with FDA keeping specific rules for service record content. Service reports should be analyzed for trends and fed into complaint handling and CAPA where appropriate. FDA's 2024 guidance on remanufacturing clarifies when work by third parties on a device goes beyond servicing and becomes remanufacturing, making them a manufacturer.

Why it matters

Active area of policy discussion - FDA has held public meetings on third-party servicing and parts availability.

Common pitfalls

•Failing to document servicing procedures and records adequately can lead to non-compliance during FDA inspections.
•Not treating servicing events that meet MDR criteria as complaints can result in underreporting adverse events and potential regulatory enforcement.
•Manufacturers sometimes overlook the need to evaluate third-party servicing activities against their own quality system requirements.
•Assuming that servicing responsibilities end once a device is sold without considering the full product lifecycle can lead to quality system gaps.
•Inadequate training for personnel performing servicing can compromise device safety and effectiveness.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.